GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Decrease in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a large decrease in short interest in March. As of March 13th, there was short interest totaling 1,019,371 shares, a decrease of 51.2% from the February 26th total of 2,089,377 shares. Based on an average daily volume of 729,020 shares, the short-interest ratio is presently 1.4 days. Approximately 3.3% of the company’s stock are short sold.

GT Biopharma Stock Performance

GT Biopharma stock traded down $0.04 during midday trading on Friday, hitting $0.41. 1,124,936 shares of the stock were exchanged, compared to its average volume of 700,959. GT Biopharma has a 1 year low of $0.39 and a 1 year high of $3.85. The company has a 50 day moving average price of $0.51 and a two-hundred day moving average price of $0.65.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC acquired a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned approximately 0.47% of GT Biopharma as of its most recent SEC filing. 8.15% of the stock is owned by institutional investors and hedge funds.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).